NXY-059 for the treatment of stroke [1]

New England Journal of Medicine

Volumn 357, Issue 21, 2007, Pages 2198-2199

  Savitz, Sean I ^a   Fisher, Marc ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFECT; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; STROKE; TREATMENT OUTCOME;

EID: 36349016114     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072612     Document Type: Letter

References (5)

1. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71.
2. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8.
3. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007;205:20-5.
4. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjö BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778-87.
5. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino) methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33:1411-5.